Allakos(ALLK)
搜索文档
All You Need to Know About Allakos (ALLK) Rating Upgrade to Buy
ZACKS· 2024-11-12 02:06
Investors might want to bet on Allakos Inc. (ALLK) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual inve ...
Allakos Runs Up Into A Near-Term Catalyst
Seeking Alpha· 2024-11-07 18:13
Scientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure: I/we have a beneficial long position in the shares of ALLK either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than f ...
Allakos(ALLK) - 2024 Q3 - Quarterly Report
2024-11-07 05:10
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _________ Commission File Number: 001-38582 Allakos Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 45-4798831 (State or ot ...
Allakos(ALLK) - 2024 Q3 - Quarterly Results
2024-11-07 05:07
Exhibit 99.1 Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results SAN CARLOS, Calif., November 6, 2024 (GLOBE NEWSWIRE) – Allakos Inc. (the "Company") (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2024. Recent Allakos Events • Reported safety, pharmacokinetics (PK), and pharmacodynamic (P ...
Allakos Provides Business Update and Reports Third Quarter 2024 Financial Results
GlobeNewswire News Room· 2024-11-07 05:02
SAN CARLOS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2024. Recent Allakos Events Reported safety, pharmacokinetics (PK), and pharmacodynamic (PD) results from the Phase 1 trial of subcutaneous (SC) AK006 in healthy volunteers. Bioavailability ...
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
GlobeNewswire News Room· 2024-10-11 04:02
– Subcutaneously administered AK006 showed approximately 77% bioavailability and prolonged receptor occupancy on mast cells –– Subcutaneous AK006 was well-tolerated with a favorable safety profile –– Top-line Phase 1 results of Intravenous AK006 in patients with CSU are expected in early Q1 of 2025 – SAN CARLOS, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced results from the Phase ...
Allakos(ALLK) - 2024 Q2 - Quarterly Report
2024-08-08 04:08
产品研发和临床试验 - 公司正在开发治疗过敏、炎症和增殖性疾病的免疫调节受体靶向药物AK006[82] - AK006在临床前研究中显示了广泛的动物疾病模型中的活性,包括肥大细胞疾病[82] - 公司正在进行AK006的IV和SC给药途径的I期临床试验,结果显示AK006安全性良好,能够达到皮肤肥大细胞的高水平受体占有率[82,83] - 公司计划在2024年底前获得AK006在慢性自发性荨麻疹患者中的临床试验数据[82] - 公司已开发了AK006皮下给药的制剂,并计划在后续临床开发中使用该给药途径[82] 公司重组和人员调整 - 公司决定不再继续开发lirentelimab(AK002),并实施了2024年重组计划,减少了约50%的员工[83] 财务状况 - 截至2024年6月30日,公司拥有1.231亿美元的现金、现金等价物和可用证券,预计可为未来12个月的计划运营提供资金支持[83] - 公司预计在未来几年内不会产生任何产品销售收入[84] - 公司的研发支出主要包括临床试验、制造和人员相关成本[85-89] - 公司预计下半年的支出将低于上半年,主要是由于lirentelimab相关支出的减少以及2024年重组计划的实施[90] - 公司一般及行政费用在2024年上半年有所下降,主要是由于2024年重组计划相关的裁员费用[92] - 公司在2024年第一季度对长期资产计提了27.3百万美元的减值损失,主要是由于公司股价和市值大幅下降,导致存在潜在减值[93] - 公司2024年上半年研发费用为54.2百万美元,同比下降6.2百万美元,主要是由于薪酬成本和其他研发费用的减少[107] - 公司2024年上半年一般及行政费用为20.1百万美元,同比下降2.4百万美元,主要是由于薪酬成本和其他费用的减少[108] - 公司2024年上半年计提了27.3百万美元的长期资产减值损失[109] - 公司2024年6月30日的现金、现金等价物和投资总额为123.1百万美元,预计未来12个月内可以维持当前运营水平[113] 融资活动 - 公司2022年5月和2023年11月分别完成了250百万美元的股票发行注册[114] - 公司2022年8月启动了75百万美元的"随时发行"股票计划,截至2024年6月30日尚有74百万美元可供发行[115] - 公司未来将继续需要额外资金来开发产品候选药物、实现商业化批准并维持运营[121] - 公司计划通过私募或公开股权融资、债务融资或其他途径如战略合作来筹集资金[121] - 如果无法及时筹集到足够资金,公司可能需要推迟、减少或终止部分研发工作,或将产品候选药物在某些地区或适应症的权利出售或授权给他人[121] - 发行额外股权可能会导致股东权益被摊薄,未来的股权或债务融资可能包含不利于公司及其股东的条款[122] 合同义务和承诺 - 公司的合同义务和承诺主要涉及经营租赁和不可取消的采购义务[123] - 公司可能需要为取消承诺的采购义务或提前终止协议支付违约金[123] - 公司未来可能需要为新的合作研究、临床试验、商业制造等签订大额预付款和长期资本承诺的协议[123] 其他 - 公司自成立以来未进行任何资产负债表外安排[125] - 作为小报告公司,公司无需提供市场风险的定量和定性披露[126]
Allakos(ALLK) - 2024 Q2 - Quarterly Results
2024-08-08 04:06
财务状况 - 公司于2024年6月30日结束的第二季度现金、现金等价物和投资总额为1.231亿美元[4] - 公司预计2024年底的现金、现金等价物和投资总额将在8,100万美元至8,600万美元之间[4] 费用管理 - 研发费用从2023年第二季度的2,730万美元下降至2024年第二季度的1,942万美元,降幅为790万美元[5] - 一般及行政费用从2023年第二季度的1,053万美元下降至2024年第二季度的921万美元,降幅为130万美元[6] - 公司在2024年第二季度支付了约100万美元的相关费用[4] - 公司预计2024年将支付约3,000万美元的退出利仑特利单抗开发项目的相关费用,其中2024年前6个月已支付1,300万美元[4] 经营业绩 - 公司在2024年第二季度的净亏损为2,667万美元,相比2023年第二季度的3,512万美元有所下降[6] 业务发展 - 公司正在进行重组活动,将现金使用期限延长至2026年中期[4] - 公司正在开展AK006的多项临床试验,包括慢性自发性荨麻疹的随机双盲安慰剂对照试验[2,3] - 公司已完成AK006静脉给药和皮下给药的健康受试者试验,并将在2024年第三季度和年底公布相关结果[2,3]
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
GlobeNewswire News Room· 2024-08-08 04:02
SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2024. Recent Allakos Events Initiated the randomized, double-blind, placebo-controlled Phase 1 trial of intravenous (IV) AK006 in patients with chronic spontaneous urticaria.Completed dosing in ...
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
Newsfilter· 2024-06-26 04:02
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments –– Skin biopsies from subjects treated with AK006 show high receptor occupancy –– AK006 was well-tolerated with a favorable safety profile – SAN CARLOS, Calif., June 25, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced positive results from the single and multiple ascending Phase ...